Journal Article

DKFZ-2022-01282

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression.

Catanzaro, G. ; Besharat, Z. M. ; Carai, A. ; Jäger, N.DKFZ* ; Splendiani, E. ; Colin, C. ; Po, A. ; Chiacchiarini, M. ; Citarella, A. ; Gianno, F. ; Cacchione, A. ; Miele, E. ; Diomedi Camassei, F. ; Gessi, M. ; Massimi, L. ; Locatelli, F. ; Jones, D.DKFZ* ; Figarella-Branger, D. ; Pfister, S.DKFZ* ; Mastronuzzi, A. ; Giangaspero, F. ; Ferretti, E.

2022
Biomed Central London

This record in other databases:  

Please use a persistent id in citations: doi:10.1186/s40364-022-00389-x

Abstract: Pediatric low-grade gliomas (pLGGs), particularly incompletely resected supratentorial tumours, can undergo progression after surgery. However to date, there are no predictive biomarkers for progression. Here, we aimed to identify pLGG-specific microRNA signatures and evaluate their value as a prognostic tool.We identified and validated supratentorial incompletey resected pLGG-specific microRNAs in independent cohorts from four European Pediatric Neuro-Oncology Centres.These microRNAs demonstrated high accuracy in differentiating patients with or without progression. Specifically, incompletely resected supratentorial pLGGs with disease progression showed significantly higher miR-1248 combined with lower miR-376a-3p and miR-888-5p levels than tumours without progression. A significant (p < 0.001) prognostic performance for miR-1248 was reported with an area under the curve (AUC) of 1.00. We also highlighted a critical oncogenic role for miR-1248 in gliomas tumours. Indeed, high miR-1248 levels maintain low its validated target genes (CDKN1A (p21)/FRK/SPOP/VHL/MTAP) and consequently sustain the activation of oncogenic pathways.Altogether, we provide a novel molecular biomarker able to successfully identify pLGG patients associated with disease progression that could support the clinicians in the decision-making strategy, advancing personalized medicine.

Keyword(s): Pediatric low-grade gliomas ; Personalized medicine ; Prognostic biomarker ; Risk stratification ; Tumour progression ; miR-1248

---

Contributing Institute(s):

1. B062 Pädiatrische Neuroonkologie (B062)
2. DKTK HD zentral (HD01)
3. Pediatric Glioma (B360)

Research Program(s):

1. 312 - Funktionelle und strukturelle Genomforschung (POF4-312) (POF4-312)

Appears in the scientific report 2022

---

Database coverage:
; ; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---